Gilead Sciences (NASDAQ:GILD) Upgraded at ValuEngine

ValuEngine upgraded shares of Gilead Sciences (NASDAQ:GILD) from a sell rating to a hold rating in a research report report published on Thursday, ValuEngine reports.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Gilead Sciences from a buy rating to a hold rating in a research note on Wednesday, June 5th. Morgan Stanley set a $82.00 price target on shares of Gilead Sciences and gave the company a hold rating in a research note on Monday, July 15th. Evercore ISI reaffirmed a buy rating on shares of Gilead Sciences in a research note on Friday, May 17th. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the company a buy rating in a research note on Friday, July 12th. Finally, Citigroup raised shares of Gilead Sciences from a neutral rating to a buy rating and set a $66.80 price target for the company in a research note on Wednesday, May 22nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of Buy and a consensus target price of $82.29.

GILD stock traded down $0.52 during midday trading on Thursday, hitting $64.95. The stock had a trading volume of 6,753,067 shares, compared to its average volume of 6,022,869. The firm has a market cap of $83.47 billion, a price-to-earnings ratio of 10.56, a P/E/G ratio of 3.93 and a beta of 1.16. The company has a current ratio of 3.85, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. Gilead Sciences has a 1-year low of $60.32 and a 1-year high of $79.61. The company’s fifty day moving average price is $67.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. During the same period in the previous year, the firm posted $1.91 earnings per share. The business’s revenue was down 2.8% compared to the same quarter last year. Analysts predict that Gilead Sciences will post 6.64 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.88%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s payout ratio is presently 40.98%.

In other news, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at $2,238,277.86. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Creative Financial Designs Inc. ADV grew its position in Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 165 shares in the last quarter. Trustcore Financial Services LLC bought a new stake in Gilead Sciences in the 1st quarter worth about $34,000. Weaver Consulting Group purchased a new position in Gilead Sciences in the first quarter valued at about $34,000. Legacy Advisors LLC purchased a new position in Gilead Sciences in the second quarter valued at about $37,000. Finally, Founders Capital Management boosted its stake in Gilead Sciences by 50.0% in the first quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 200 shares during the last quarter. 78.85% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Google Finance Portfolio Tips and Tricks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.